Business
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
LONDON & NEW YORK, March 24, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.
About this update from Compass, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4426,"height":796,"url":"https://media.zenfs.com/en/business-wire.com/6a0e5ce72e34d1499121e14b14f78fe5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7sSeem3C1wMJyix9Ryfg9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3Mw--/https://media.zenfs.com/en/business-wire.com/6a0e5ce72e34d1499121e14b14f78fe5","width":960,"height":173},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ypm.UKM1WHTUxOyh3hDV2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MzI-/https://media.zenfs.com/en/business-wire.com/6a0e5ce72e34d1499121e14b14f78fe5","width":1200,"height":216}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile","length":230,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Across three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before","length":253,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4","length":136,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch","length":140,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Phase 2b/3 trial in PTSD initiating, following FDA acceptance of IND application","length":80,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Successful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":955,"olType":false},{"type":"text","content":"LONDON & NEW YORK, March 24, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to...